Products E2007 (perampanel) + E2007 (perampanel) + Placebo
E2007 (perampanel) + E2007 (perampanel) + Placebo Phase 3 Completed 📈 Rising Refractory Partial Seizures
Refractory Partial Seizures
Apr 30, 2008 → Oct 19, 2010
About E2007 (perampanel) + E2007 (perampanel) + Placebo E2007 (perampanel) + E2007 (perampanel) + Placebo is a phase 3 stage product being developed by Eisai for Refractory Partial Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT00699972. Target conditions include Refractory Partial Seizures.
Clinical Trials (2) NCT ID Phase Status Start Completion Indication NCT00699582 Phase 3 Completed May 1, 2008 Jan 1, 2011 Refractory Partial Seizures NCT00699972 Phase 3 Completed Apr 30, 2008 Oct 19, 2010 Refractory Partial Seizures
Product Company Stage Hype Score Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 agenT-797 MiNK Therapeutics Phase 1 eFT508 + Avelumab eFFECTOR Therapeutics Phase 2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 Valemetostat Tosylate Daiichi Sankyo Phase 2 Enzalutamide Astellas Pharma Phase 2 ASP1650 Astellas Pharma Phase 2 YM598 Astellas Pharma Phase 2 erlotinib + etoposide Astellas Pharma Phase 2 Mitoxantrone Hydrochloride Liposome & Enlonstobart Sun Pharmaceutical Phase 1/2 Lenvatinib + Everolimus Eisai Phase 1/2 perampanel + perampanel + perampanel + Placebo Eisai Phase 3 Eribulin mesilate + Irinotecan hydrochloride Eisai Phase 1/2 perampanel Eisai Phase 2 rabeprazole sodium Eisai Pre-clinical Lenvatinib Eisai Phase 2 E2007 (perampanel) + E2007 (perampanel) + Placebo Eisai Phase 3 Tazemetostat Eisai Phase 2 Rufinamide Eisai Phase 3 Lenvatinib + Moxifloxacin 400 mg + Placebos (matched to 4 mg and 10 mg lenvatinib capsules). Eisai Phase 1
Other Products from Eisai